Research Nester Logo.jpg
Optic Neuritis Treatment Market revenue to hit USD 450 Million by 2035, says Research Nester
27. September 2023 07:00 ET | Research Nester
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global optic neuritis treatment market size is slated to expand at ~ 5% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD...
Optic Neuritis Treatment Market Optic Neuritis Treatment Market Growth Rate By Region
Steroidal Therapy Segment Soars as Optic Neuritis Treatment Market Expands 2023 to 2028
04. September 2023 07:03 ET | Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Optic Neuritis Treatment Market - Growth, Trends, and Forecasts (2023 - 2028)" report has been added to ResearchAndMarkets.com's offering.The optic...
Figure 1
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515, Extending Market Exclusivity to Late 2041
20. September 2022 12:47 ET | Trethera Corporation
LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Figure 1
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
07. September 2022 12:37 ET | Trethera Corporation
LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Figure 1
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
30. August 2022 10:37 ET | Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...
Figure 1
Trethera Receives U.S. Patent Office Notice of Allowance Covering TRE-515 Structural Claims, Extending Protections to Late 2041
17. August 2022 12:38 ET | Trethera Corporation
LOS ANGELES, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Figure 1
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis
09. August 2022 12:47 ET | Trethera Corporation
LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...